Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
SVB Leerink Maintains Market Perform on Adaptimmune Therapeutics, Lowers Price Target to $3
SVB Leerink analyst Jonathan Chang maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Market Perform and lowers the price target from $7 to $3.
Adaptimmune Therapeutics: Q4 Earnings Insights
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Adaptimmune Therapeutics Q4 EPS $(0.04) Misses $0.14 Estimate, Sales $1.42M Miss $96.45M Estimate
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.14 by 128.57 percent. This is a 83.33 percent increase over losses of $(0.24) per
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell
• F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
A Preview Of Adaptimmune Therapeutics’s Earnings
Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement.
Analysts estimate that Adaptimmune Therapeutics will report an earnings per share (EPS) of $0.14.
